Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma

Project Oncology®

ReachMD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 ReachMD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

2M ago

MP3•에피소드 홈

Host: Jesus G. Berdeja, MD
Guest: Nicholas G. Barkemeyer, MPAS
Guest: Ajai Chari, MD
Guest: Harvey Church
Guest: Amy Gebhardt
Guest: Steven Morrow
Release date: 7/18/2024
Expiration date: 7/18/2025
Estimated time to complete: 1.0 hour

This activity is not accredited for CME/CE credit.

This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.

162 에피소드